By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic said Tuesday that it has signed a multi-year research agreement with Novartis, under which the drug firm will use SomaLogics' proteomics technology to accelerate its drug discovery and development efforts.

Larry Gold, CEO of Boulder, Colo.-based SomaLogic, said in a statement that the alliance will help Novartis "define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.